ADMA vs ASND: fair value comparison
ADMA Biologics, Inc. and Ascendis Pharma A/S · Updated 2026-10-19
ASND reports in EUR, so no same-currency fair-value verdict is published for it. Within Healthcare, ADMA currently ranks higher by quality score.
| ADMA | ASND | |
|---|---|---|
| Verdict | Undervalued | Awaiting full valuation |
| Last price | $10.68 | $227.31 |
| 12-month range | $7.60–$20.38 | $196.01–$277.18 |
| Rank by discount to fair value | #97 of 108 Healthcare | — |
| Rank by quality score | #15 of 301 Healthcare | #16 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | High |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: ADMA fair value analysis · ASND fair value analysis